Anticoagulants Clinical Trial
Official title:
Optimization of Anticoagulant Therapy in Outpatient Practice
NCT number | NCT05319340 |
Other study ID # | 678657 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 15, 2014 |
Est. completion date | March 2, 2021 |
Verified date | March 2021 |
Source | I.M. Sechenov First Moscow State Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Single-institution uncontrolled open-label trial.
Status | Completed |
Enrollment | 1000 |
Est. completion date | March 2, 2021 |
Est. primary completion date | March 2, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | Inclusion Criteria: - the age above 18 - indications for the anticoagulant therapy - informed consent for inclusion into trials Exclusion Criteria: - denial to proceed in the trial Non-inclusion criteria: pregnancy and lactation - Intracerebral hemorrhage within three preceding months - severe mental disorders* which could possibly affect the anticoagulant therapy dosage schedule - anemia and a decrease in Hb by ?100 GM/DL* - active gastroduodenal ulcer - active bleeding during the preceding month - other intensive bleeding instances as per the TIMI Score within three weeks before the inclusion - severe hepatic impairment for over 10 points under the Child-Pugh Score - oncology disease with the life expectancy less than one year |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
I.M. Sechenov First Moscow State Medical University |
Chashkina MI, Kozlovskaya NL, Andreev DA, Ananicheva NA, Bykova AA, Salpagarova ZK, Syrkin AL. [Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments]. Kardiologiia. 2020 Mar 5;60(2):41-46. doi: 10.18087/cardio.2020.2.n823. Russian. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | minor bleeding | Minor bleeding shall mean any visually observed bleeding, including that discovered with various imaging methods, which cause a decrease in HB by less than 30 GM/DL or Ht by less than 9%. | in 1-2-3-6 years after the anticoagulant therapy is prescribed | |
Primary | kidney compliance with the anticoagulant therapy and its safety and trends in the kidney function | During a visit to the clinic, the patient will be surveyed and tested for the creatinine level | Evaluation of GFR, bleeding and thrombotic complications after 2 years | |
Primary | death due to any cause | phone survey when patients are invited to the clinic | in six years after the anticoagulant therapy is prescribed | |
Primary | cardiovascular mortality | Phone survey when patients are invited to the clinic. The term cardiovascular mortality means a set of fatal heart attacks, fatal strokes, sudden death, fatal thromboembolism. | Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 2 years | |
Primary | kidney function trend | phone survey when patients are invited to the clinic for testing the creatinine level and further estimation of the glomerular filtration rate | Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 3 years | |
Primary | intensive bleeding | phone survey when patients are invited to the clinic. | Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 6 years | |
Secondary | frequency of thromboembolic events | patients will be surveyed upon their visit to the clinic. Thromboembolic events shall mean non-fatal embolic strokes, systemic embolism, acute coronary syndrome (to be corroborated with documents). | in 1-2-3-6 years after the anticoagulant therapy is prescribed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02128841 -
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
|
Phase 2 | |
Recruiting |
NCT03666962 -
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
|
||
Recruiting |
NCT03670446 -
Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants:A Study on Behavioral Patterns
|
N/A | |
Recruiting |
NCT04796714 -
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
|
Phase 4 | |
Completed |
NCT01033279 -
Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy
|
N/A | |
Completed |
NCT00287313 -
Daily Vitamin K in Patients on Warfarin With Unstable INRs
|
N/A | |
Completed |
NCT00222638 -
Influenza Vaccination and Oral Anticoagulant Therapy
|
Phase 4 | |
Active, not recruiting |
NCT06203795 -
Dialysis Performance of the FX CorAL Membrane
|
N/A | |
Completed |
NCT03864900 -
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
|
N/A | |
Active, not recruiting |
NCT06401863 -
Shared Decision for Drug Interactions in Oral Anticoagulation
|
N/A | |
Not yet recruiting |
NCT04977076 -
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
|
N/A | |
Recruiting |
NCT04861103 -
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
|
Phase 4 | |
Completed |
NCT01653405 -
Improving Anticoagulation Control in VISN 1
|
N/A | |
Not yet recruiting |
NCT05820854 -
Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
|
||
Completed |
NCT04681482 -
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
|
||
Not yet recruiting |
NCT06137794 -
Application of "I-Anticoagulation"in Patients With Atrial Fibrillation
|
N/A | |
Completed |
NCT02103101 -
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
|
N/A | |
Completed |
NCT05065502 -
MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings
|
N/A | |
Recruiting |
NCT03965208 -
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation
|
Phase 4 | |
Completed |
NCT03318393 -
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
|
Phase 4 |